



FINANCIAL TEAR SHEET

Corporate Profile

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Sanfilippo disorder, Batten disease, Fanconi anemia and other rare disorders.

Primary IR Contact

Andre'a Lucca
 Director of Communications
 PlasmaTech
 Biopharmaceuticals, Inc.
Phone: 212-786-6208
E-mail:
 alucca@plasmatechbio.com

Stock Performance

ABEO (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$16.55
Change (%)	▲ 0.65 (4.09%)
Volume	2,011,261
52 Week Low	\$4.55
Market Cap	\$782,902,467
Rolling EPS	-0.70
PE Ratio	0
Shares Outstanding	47,305,285



Data as of June 15, 2018 4:00 p.m. ET

Recent Press Releases & Upcoming Events

June 6, 2018
Abeona Therapeutics Announces
Upcoming Presentation at Jefferies 2018
Global Healthcare Conference

There are currently no events scheduled.

May 31, 2018
Abeona Therapeutics Announces Opening
of Commercial Gene & Cell Therapy
Manufacturing Facility in Ohio

May 18, 2018
Abeona Therapeutics Provides Clinical
Update on MPS IIIA Gene Therapy Trial at
the 21st Annual ASGCT Meeting

SEC Filings

Corporate Governance

Filing Date	Form
June 7, 2018	EFFECT
June 1, 2018	S-3/A
May 23, 2018	4
May 23, 2018	4

Data provided by Nasdaq. Minimum 15 minutes delayed.